Ozempic vs Semaglutide for Weight Loss: Are They Actually Different?

If you’ve spent any time researching weight loss medications, you’ve almost certainly encountered both the names Ozempic and semaglutide — sometimes used interchangeably, sometimes treated as entirely different drugs. The confusion is understandable, but the distinction matters if you’re trying to make an informed decision about your health.

Here’s the short answer: Ozempic is semaglutide. Ozempic is simply the brand name for semaglutide manufactured by Novo Nordisk, originally approved by the FDA for type 2 diabetes management. The active molecule in the injection is identical whether a label says Ozempic, Wegovy, or generic semaglutide. What differs between these products — and what actually changes your results — is the approved dose, the intended use, and how aggressively you titrate upward.

Same Molecule, Different Doses — and That Gap Is Enormous

Ozempic is approved at doses up to 2 mg weekly for blood sugar control in type 2 diabetes, though many physicians prescribe it off-label for weight loss. Wegovy, the same semaglutide molecule, is approved specifically for chronic weight management at a maximum dose of 2.4 mg weekly. That 0.4 mg difference sounds minor, but the clinical outcomes tell a different story.

The STEP 3 randomized clinical trial published in JAMA put semaglutide 2.4 mg head-to-head against placebo in 611 adults with overweight or obesity, pairing both groups with intensive behavioral therapy. After 68 weeks, the semaglutide group lost an average of 16.0% of their body weight compared to just 5.7% in the placebo group — a difference of more than 10 percentage points. Over 86% of participants on semaglutide lost at least 5% of their body weight, and more than half lost 15% or greater. These are not modest numbers. If you weigh 240 pounds, a 16% reduction means dropping roughly 38 pounds.

Maintaining that loss is where the real story gets interesting. The STEP 4 trial in JAMA followed participants who had already lost an average of 10.6% of their body weight during a 20-week semaglutide run-in, then randomly assigned them to continue or switch to placebo. Those who stayed on semaglutide lost an additional 7.9% over the next 48 weeks. Those who switched to placebo regained 6.9%. The divergence between groups — nearly 15 percentage points — makes it clear that semaglutide’s effect is continuous rather than front-loaded. Stop the drug, and the weight comes back.

How Semaglutide Compares to Other Options

If you’re weighing semaglutide against other GLP-1 medications, the clinical picture is fairly decisive. The STEP 8 trial in JAMA ran a direct comparison between once-weekly semaglutide 2.4 mg and once-daily liraglutide 3.0 mg — both injectable GLP-1 receptor agonists — in adults without diabetes. At 68 weeks, semaglutide users lost 15.8% of their body weight versus 6.4% for liraglutide, a difference of 9.4 percentage points. Semaglutide also had a meaningfully better tolerability profile: 27.6% of liraglutide participants discontinued treatment compared to just 13.5% on semaglutide.

The newer dual agonist tirzepatide — which targets both GLP-1 and GIP receptors — does appear to outperform semaglutide on weight loss metrics. A 2024 real-world cohort study in JAMA Internal Medicine analyzing over 18,000 propensity-matched adults found tirzepatide users were 3.24 times more likely to achieve 15% or greater weight loss than semaglutide users, with an average difference of 6.9% more weight lost at 12 months. That said, semaglutide remains a proven, widely available, and highly effective option — and a 2025 systematic review in the Annals of Internal Medicine covering 26 randomized controlled trials confirmed that GLP-1 receptor agonists as a class are efficacious for weight loss in adults without diabetes, with safety concerns being predominantly gastrointestinal in nature.

Speaking of gastrointestinal side effects — nausea, vomiting, and constipation are real and common with all formulations of semaglutide, affecting anywhere from 49% to 84% of users across trials. Slow dose titration is the standard approach for managing them, and most people find symptoms diminish significantly after the first few weeks at a stable dose.

What This Means For You

If your doctor has prescribed Ozempic for weight loss, you’re receiving semaglutide — the same active compound studied in the STEP trials — just at a dose that may be lower than what was used in those landmark studies. Whether that’s sufficient depends on your response and your physician’s titration plan. If maximum weight loss efficacy is the goal, the 2.4 mg weekly dose studied in Wegovy trials is where the data is strongest. The conversation worth having with your doctor isn’t “Ozempic vs semaglutide” — it’s “what dose do I need, and what does long-term treatment look like for me?” Because the evidence is unambiguous on one point: stop the medication without a lifestyle foundation to stand on, and the weight returns.